Free tool
FDA Approval Tracker
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations
Matching approvals
592
2015 to 2026
Breakthrough
156
Accelerated
103
Priority review
361
Orphan
298
By year
NDAs and BLAs matching the filters.
- NDA
- BLA
View as table
| Year | NDA | BLA |
|---|---|---|
| 2015 | 34 | 12 |
| 2016 | 14 | 8 |
| 2017 | 37 | 12 |
| 2018 | 44 | 17 |
| 2019 | 39 | 10 |
| 2020 | 45 | 14 |
| 2021 | 40 | 14 |
| 2022 | 25 | 15 |
| 2023 | 41 | 17 |
| 2024 | 36 | 17 |
| 2025 | 37 | 14 |
| 2026 | 38 | 12 |
592 approvals
Newest first. Hover a badge for what it means.
- Klygefa (Gefurulimab) · Alexion PharmNov 13, 2026Original approval · BLA 761488NovelOrphan
To treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis
- Pimjetmi (Pimicotinib) · Emd SeronoNov 10, 2026
To treat adults with symptomatic tenosynovial giant cell tumors in whom surgical resection may cause worsening functional limitation or severe morbidity
- Sunharbo (Asundexian) · Bayer HealthcareNov 9, 2026
To reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack
- Hibsago (Bepirovirsen Sodium) · GlaxosmithklineOct 20, 2026
To treat chronic hepatitis B virus infection in certain adults without cirrhosis, in combination with existing antiviral therapy
- Hovilpri (Pritelivir Mesylate) · Aicuris Anti-InfectOct 9, 2026
To treat adults with weakened immune systems who have mucocutaneous lesions caused by herpes simplex virus infection and have not responded to other therapies
- Emcitate (Tiratricol) · Rare ThyroidSep 28, 2026
To treat peripheral thyrotoxicosis in patients with MCT8 deficiency
- Juvmo (Tavapadon) · AbbvieSep 25, 2026
To treat Parkinson's disease in adults
- Atebrioz (Zilurgisertib Fumarate) · MirumSep 25, 2026
To reduce the volume of total new heterotopic ossification in adults and pediatric patients 12 years and older with fibrodysplasia ossificans progressiva
- Lyrfigtu (Lirafugratinib Hydrochloride) · ElevarSep 23, 2026
To adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 gene fusion or other rearrangement
- Onswik (Insulin Efsitora Alfa-Gobe) · Eli Lilly and COSep 23, 2026
To improve glycemic control in adults with type 2 diabetes mellitus, as an adjunct to diet and exercise
- Isembyld (Apitegromab-Mstn) · Scholar Rock INCSep 11, 2026
To treat spinal muscular atrophy in adults and pediatric patients 2 years of age and older who are currently receiving an SMN2-targeted treatment
- Pixclara (Floretyrosine F-18) · TelixSep 11, 2026
To use with positron emission tomography to differentiate recurrent or progressive glioma from treatment-related change in conjunction with other diagnostic evaluations
- Etcamah (Camizestrant) · AstrazenecaSep 4, 2026
To treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy
- Zanvastro (Zilganersen Sodium) · Ionis Pharms INCSep 3, 2026
To treat Alexander disease in pediatric and adult patients
- Mimrylo (Rusfertide Acetate) · Takeda Pharms AmAug 28, 2026
To treat erythrocytosis in adults with polycythemia vera
- Lisraya (Brepocitinib Tosylate) · Priovant TherapAug 27, 2026
To treat dermatomyositis in adults
- Rasonque (Daraxonrasib) · Revolution MedicinesAug 26, 2026
To treat metastatic pancreatic cancer
- Pasatru (Garetosmab-Grts) · Regeneron Pharmaceuticals, INCAug 19, 2026
To reduce new heterotopic ossification and clinician-assessed disease flare-ups in adults with fibrodysplasia ossificans progressiva
- Zenbexus (Iberdomide Hydrochloride) · Bristol Myers SquibbAug 13, 2026
To be used in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent
- Tauklarify (Florquinitau F-18) · Cerveau LantheusAug 13, 2026
To be used for positron emission tomography of the brain in adults with cognitive impairment who are being evaluated for Alzheimer disease to identify patients with tau neurofibrillary tangle pathology
- Orzeyful (Oveporexton) · Takeda Pharms USAAug 5, 2026
To treat narcolepsy type 1
- Simtriyo (Centanafadine Hydrochloride) · OtsukaJul 24, 2026
To treat attention-deficit hyperactivity disorder
- Lytenava (Bevacizumab-Vikg) · Outlook Therapeutics, Inc.Jul 24, 2026
To treat patients with neovascular (wet) age-related macular degeneration
- Jideytro (Zidesamtinib) · NuvalentJul 22, 2026
To treat adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer after receiving a ROS1 kinase inhibitor
- Lipfendra (Enlicitide Decanoate) · MsdJul 15, 2026
To reduce low-density lipoprotein cholesterol
- Revtorpyk (Gedatolisib) · CelcuityJul 14, 2026
In combination with fulvestran, to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting
- Trutakna (Atacicept-Vymj) · Vera Therapeutics Inc.Jul 7, 2026
To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression
- Lumvoa (Veligrotug-Vvze) · Viridian Therapeutics INCJun 26, 2026
To treat thyroid eye disease
- Utebzi (Tebipenem Pivoxil Hydrobromide) · GlaxosmithklineJun 17, 2026
To treat complicated urinary tract infections, including pyelonephritis, caused by several susceptible microorganisms in adults who have limited or no alternative oral treatment options
- Ambelvist (Gadoquatrane) · Bayer HealthcareJun 12, 2026
To detect and visualize lesions with abnormal vascularity, in conjunction with MRI
- Zaynich (Cefepime Hydrochloride, Zidebactam) · Wockhardt Bio AGMay 29, 2026
To treat complicated urinary tract infections, including pyelonephritis, caused by designated susceptible microorganisms
- Cypsedo (Cipepofol) · HaiscoMay 29, 2026
To induce general anesthesia in adults undergoing surgery
- Xocova (Ensitrelvir) · ShionogiMay 29, 2026
To use as post-exposure prophylaxis of coronavirus disease 2019 (COVID-19) following contact with an individual who has COVID-19
- Decnupaz (Pivekimab Sunirine-Pvzy) · Abbvie INCMay 27, 2026
To treat adults with blastic plasmacytoid dendritic cell neoplasm
- Hepcludex (Bulevirtide-Gmod) · Gilead Sciences INCMay 22, 2026Original approval · BLA 761468NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat chronic hepatitis delta virus infection in adults without cirrhosis or with compensated cirrhosis
- Baxfendy (Baxdrostat) · Astrazeneca AbMay 15, 2026
To treat hypertension in combination with other antihypertensive drugs
- Beqalzi (Sonrotoclax) · Beone Medicines USAMay 13, 2026Original approval · NDA 220711NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor
- Veppanu (Vepdegestrant) · Rigel PharmsMay 1, 2026
To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy
- Idvynso (Doravirine, Islatravir) · MsdApr 20, 2026
To treat HIV-1 infection (as a complete regimen) in adults to replace the current antiretroviral regimen in those who are virologically-suppressed on a stable antiretroviral regimen with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine
- Foundayo (Orforglipron Calcium) · Eli Lilly and COApr 1, 2026
To reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity
- Awiqli Flextouch (Insulin Icodec) · Novo Nordisk INCMar 26, 2026
- Lifyorli (Copackaged) (Relacorilant) · Corcept TherapMar 25, 2026
- Avlayah (Tividenofusp Alfa-Eknm) · Denali Therapeutics Inc.Mar 24, 2026Original approval · BLA 761485NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II)
- Icotyde (Icotrokinra Hydrochloride) · Janssen BiotechMar 17, 2026
To treat moderate-to-severe plaque psoriasis in patients 12 years and older who weigh at least 40 kg and who are candidates for systemic therapy or phototherapy
- Lynavoy (Linerixibat) · InterceptMar 17, 2026
To treat cholestatic pruritus associated with primary biliary cholangitis
- Yuviwel (Navepegritide) · AscendisFeb 27, 2026
To increase linear growth in pediatric patients 2 years and older with achondroplasia with open epiphyses
- Loargys (Pegzilarginase-Nbln) · Immedica Pharma AbFeb 23, 2026Original approval · BLA 761211NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat hyperarginemia in adults and pediatric patients two years and older with Arginase 1 Deficiency, in conjunction with dietary protein restriction
- Bysanti (Milsaperidone) · Vanda Pharms INCFeb 20, 2026
To treat schizophrenia and to treat manic or mixed episodes associated with bipolar I disorder
- Adquey (Difamilast) · Acrotech BiopharmaFeb 12, 2026
To treat mild to moderate atopic dermatitis
- Zycubo (Copper Histidinate) · Sentynl Theraps INCJan 12, 2026
To treat Menkes disease
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.